ESTRO 2025 - Abstract Book

S1029

Clinical – Head & neck

ESTRO 2025

2. Biau J et al. A multicenter prospective phase II study of postoperative hypofractionated SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer 2020;20:730. 3. Strnad V et al. Interstitial pulsed-dose-rate brachytherapy for head and neck cancer--Single-institution long-term results of 385 patients. Brachytherapy 2013;12:521–7. 4. Chen P-Y et al. Intensity-modulated radiotherapy improves outcomes in postoperative patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2012;48:747–52.

2453

Digital Poster Selective mucosal and nodal irradiation in patients of head and neck carcinoma of unknown primary (HNCUP): Emergence of primary, outcome and toxicity. Monali Swain 1 , Karthik Bathina 1 , Ashwini Budrukkar 1 , Sarbani Ghosh-Laskar 1 , Anuja Deshmukh 2 , Gouri Pantvaidya 3 , Prathamesh Pai 3 , Richa Vaish 3 , Shwetabh Sinha 1 , Anuj Kumar 1 , Samarpita Mohanty 1 , Asawari Patil 4 , Nandini Menon 5 , Vanita Naronha 5 , Kumar Prabhash 5 , Jaiprakash Agarwal 1 1 Radiation Oncology, Tata Memorial Hospital, Mumbai, India. 2 Head and NeckSurgical Oncology, Tata Memorial Hospital, Mumbai, India. 3 Head and Neck Surgical Oncology, Tata Memorial Hospital, Mumbai, India. 4 Pathology, Tata Memorial Hospital, Mumbai, India. 5 Medical Oncology, Tata Memorial Hospital, Mumbai, India Purpose/Objective: To determine the emergence of primary, outcome and toxicity of selective mucosal and nodal irradiation (SMNI) in patients of head and neck carcinoma of unknown primary (HNCUP). Material/Methods: Consecutive patients of HNCUP treated within a single head and neck unit of a tertiary cancer centre from 2018 to 2022 were included in the current study. All patients were evaluated for primary by thorough mucosal evaluation using endoscopy, biopsy with p16 and EBV status. and PET-CECT. Patients were treated with chemoradiotherapy or surgery with adjuvant treatment based on the multidisciplinary joint clinic decision. All patients were treated with IMRT for SMNI based on the viral marker status and level and site of nodal level involvement (figure 1). Response assessment PET-CECT was done at 12 weeks.